Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis

Authors Prashant Kedia, Russell D Cohen

Published 15 November 2007 Volume 2007:3(5) Pages 919—927


Prashant Kedia1, Russell D Cohen2

1Pritzker Medical School, The University of Chicago, Chicago, IL, USA; 2Clinical Inflammatory Bowel Disease, Department of Medicine, Section of Gastroenterology, The University of Chicago Medical Center, Chicago, IL, USA

Abstract: First-line therapies in the treatment of patients with mild-to-moderate ulcerative colitis are sulfasalazine or one of the mesalamine derivatives. Mesalamine is popular given its safety profile and reasonable efficacy in many patients. However, compliance is poor with regimens demanding large number of pills dosed multiple times a day and non-compliance has been correlated with disease relapse. Mesalamine requires direct contact with the inflamed colonic mucosa. To avoid proximal absorption, a variety of delivery systems has been utilized to time the release of active mesalamine to the areas affected by colitis. The most common mesalamine release mechanisms include azo-bond prodrug carriers, pH-dependent dissolution, and moisture-sensitive product dispersion. Novel technology has resulted in the development and FDA-approval of a multi-matrix release (MMX) mesalamine. Pharmacodynamic studies suggest a reliable drug delivery system with homogenous release throughout the entire colon. By incorporating the largest amount of mesalamine (1.2 g) per pill, this new product dramatically decreases the number of pills needed to attain a therapeutic daily dosage, and is the first agent approved at once-daily dosing. These factors are expected to increase patient compliance with prescribed mesalamine dosing, and in turn decrease relapse rates of active ulcerative colitis.

Keywords: mesalamine, sulfasalazine, balsalazide, olsalazine, ulcerative colitis, inflammatory bowel disease

Download Article [PDF]